Introduction The PHOTON Phase 2/3 trial demonstrated the efficacy and safety of intravitreal aflibercept 8 mg in the treatment of diabetic macular oedema (DME) [1]. SPECTRUM is a global study evaluating aflibercept 8 mg treatment of DME and neovascular age-related macular degeneration (nAMD) in routine clinical practice. This SPECTRUM analysis presents early clinical experience with aflibercept 8 mg among patients with treatment-naïve (TN) or previously treated (PT) DME.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Helmut
Contact Helmut, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack